Biotech Blueprint
Subscribe
Sign in
Home
Notes
This Week in Biotech
Deep Dives
Consulting
Archive
About
This Week in Biotech
Latest
Top
Discussions
Retatrutide Underdelivers, Novo Sues Lilly, and GSK Wins a Fast Lung Cancer Approval – This Week in Biotech #110
Lilly's triple agonist misses on cardiovascular outcomes, Novo Nordisk takes Lilly to court over "deceptively false" ads, and Trump threatens 200…
Jul 24
•
Katerina Roznik
11
Merck's Oral PCSK9 Cholesterol Pill, Lilly's $2.8B Psychedelics Buy, and Makary's Regulatory Ghost – This Week in Biotech #109
Lipfendra becomes the first oral drug to match injectable cholesterol lowering, Lilly enters psychedelics with an $2.8B AtaiBeckley acquisition, and the…
Jul 17
•
Katerina Roznik
20
2
4
AstraZeneca's Amyloid Miss, Vertex's $10B Crinetics Buy, and Kidney Disease's Two-Drug Race – This Week in Biotech #108
Eplontersen fails in a market its competitors already own, Vertex makes its biggest deal ever to diversify beyond cystic fibrosis, and Vera Therapeutics…
Jul 10
•
Katerina Roznik
9
Happy 4th of July – This Week in Biotech #107
Roche beats two KRAS drugs at once, Anthropic starts making its own drugs, and biotech's XBI hits a five year high (June 26-July 2, 2026).
Jul 3
•
Katerina Roznik
11
1
Washington Tries to Outcompete China, Lilly’s $1.9B Abbisko Bet, and Pfizer’s $43B Seagen Question – This Week in Biotech #106
HHS unveils a clinical trial reform blueprint as Lilly doubles down on Chinese discovery, Pfizer's lung cancer ADC fails, and US health spending hits…
Jun 26
•
Katerina Roznik
7
uniQure Wins a Surprise FDA Path in Huntington's, Moderna's mRNA Flu Vote, and a Record IPO Run – This Week in Biotech #105
The FDA reverses course on two products it had previously blocked, Lilly closes its fifteenth deal of 2026, and Kardigan pops 38% on debut to extend the…
Jun 19
•
Katerina Roznik
9
AstraZeneca Crashes the Obesity Party, Takeda Topples Sotyktu, and a Record Biotech IPO – This Week in Biotech #104
Elecoglipron makes obesity a four-player race, zasocitinib beats Bristol Myers Squibb head-to-head, and Parabilis prices the biggest venture-backed…
Jun 12
•
Katerina Roznik
11
1
1
China's First ASCO Plenary, a Standing Ovation for Daraxonrasib, and Washington's Counter-Move – This Week in Biotech #103
Akeso's ivonescimab beats a PD-1 inhibitor head-to-head in lung cancer, Revolution Medicines doubles survival in pancreatic cancer, and a House bill…
Jun 5
•
Katerina Roznik
6
GSK Functionally Cures Hepatitis B, Lilly's $3.8B Vaccine Pivot, and Base Editing Holds for 18 Months – This Week in Biotech #102
A landmark antisense win in 254 million patients, Lilly's tenth deal of 2026 redraws its franchise map, and Verve's base editor holds for 18 months (May…
May 29
•
Katerina Roznik
11
28% Weight Loss: Lilly's Retatrutide Just Redefined the Obesity Market – This Week in Biotech #101
Plus the covert campaign that took out Makary, and a 65% lung cancer trial win that could reshape Keytruda's future (May 15-21, 2026).
May 22
•
Katerina Roznik
9
1
Makary Resigns, BMS Bets $15B on China R&D, and Regenxbio Wins Phase 3 in Duchenne – This Week in Biotech #100
The FDA loses its commissioner amid mounting instability, BMS makes the biggest pharma-China deal of 2026, and a clean gene therapy dataset gives…
May 15
•
Katerina Roznik
6
FDA Approves the First PROTAC in History, a $1B siRNA Wave Hits Cardiometabolic Disease, and Cytokinetics Cracks Non-Obstructive HCM – This…
Targeted protein degradation gets its first regulatory template, Madrigal and GSK bet on genetically defined MASH and obesity, and aficamten wins where…
May 8
•
Katerina Roznik
14
1
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
